Cartesian Therapeutics (RNAC) News Today $17.02 -0.10 (-0.58%) (As of 11/14/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cartesian Therapeutics (NASDAQ:RNAC) Price Target Lowered to $41.00 at HC WainwrightNovember 12 at 1:19 AM | americanbankingnews.comCartesian Therapeutics Receives Buy Rating After Promising Phase 2b Trial Results and Strategic AdvancementsNovember 11 at 6:04 AM | markets.businessinsider.comCartesian Therapeutics: Uncertainty RemainsNovember 10, 2024 | seekingalpha.comBuy Recommendation for Cartesian Therapeutics: Strong Financials and Strategic Drug AdvancementsNovember 10, 2024 | markets.businessinsider.comCartesian Therapeutics (RNAC) Receives a Hold from OppenheimerNovember 10, 2024 | markets.businessinsider.comCartesian Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | tipranks.comHC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00HC Wainwright decreased their price target on Cartesian Therapeutics from $45.00 to $41.00 and set a "buy" rating for the company in a research note on Friday.November 8, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a research note on Friday.November 8, 2024 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsNovember 8, 2024 | globenewswire.comPositive Outlook for Cartesian Therapeutics: Buy Rating Driven by Promising Study Results and Strategic InitiativesNovember 8, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Cartesian Therapeutics (RNAC)November 8, 2024 | markets.businessinsider.comCartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual MeetingNovember 5, 2024 | markets.businessinsider.comBullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of StockOctober 19, 2024 | finance.yahoo.comNeedham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC restated a "buy" rating and set a $41.00 target price on shares of Cartesian Therapeutics in a report on Wednesday.October 16, 2024 | marketbeat.comCartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual MeetingOctober 15, 2024 | globenewswire.comCartesian Therapeutics (NASDAQ:RNAC) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comInsider Buying Slows, but Not for 7 These BuyersOctober 13, 2024 | 247wallst.comRenaissance Technologies LLC Sells 536,548 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Renaissance Technologies LLC trimmed its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 96.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,052 shares of the company's stoOctober 11, 2024 | marketbeat.comMarshall Wace LLP Makes New Investment in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Marshall Wace LLP purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 30,038 shares of the company's stock, valued at approximately $811,000. Marshall Wace LLP owned about 0.14%October 9, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Timothy A. Springer Purchases 5,514 SharesOctober 5, 2024 | insidertrades.comInsider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) Director Timothy A. Springer purchased 5,514 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average cost of $17.38 per share, for a total transaction of $95,833.32. Following the purchase, the director now owns 7,823,559 shares in the company, valued at $135,973,455.42. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.October 4, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Shares Gap Up - Here's WhyCartesian Therapeutics (NASDAQ:RNAC) Shares Gap Up - Should You Buy?October 4, 2024 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsOctober 4, 2024 | globenewswire.comLogos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Logos Global Management LP bought a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 90,000 shares of the company's stock, valued at approximately $2,431,00October 1, 2024 | marketbeat.comRhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Rhumbline Advisers trimmed its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 93.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 8,487 shares of the company's stock after selling 121,396 shares during the period. RhumblineSeptember 29, 2024 | marketbeat.comLogos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Logos Global Management LP purchased a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 90,000 shares ofSeptember 24, 2024 | marketbeat.comBuy Rating for Cartesian Therapeutics Backed by FDA Designation and Promising Therapy ProspectsSeptember 14, 2024 | markets.businessinsider.comCartesian Therapeutics' (RNAC) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Cartesian Therapeutics in a research note on Friday.September 13, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy ratiSeptember 12, 2024 | marketbeat.comCartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis TreatmentSeptember 10, 2024 | marketwatch.comCartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisSeptember 10, 2024 | markets.businessinsider.comCartesian's Descartes-08 Granted Rare Pediatric Disease Designation By FDA To Treat JDMSeptember 10, 2024 | markets.businessinsider.comCartesian Therapeutics Announces New Employment Inducement GrantSeptember 6, 2024 | globenewswire.comCartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Cartesian Therapeutics in a report on Wednesday.September 4, 2024 | marketbeat.comCartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15September 3, 2024 | globenewswire.comHall Laurie J Trustee Has $48,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Hall Laurie J Trustee reduced its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 96.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,759 shares of the company's stock after sellingAugust 20, 2024 | marketbeat.comVanguard Group Inc. Purchases New Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Vanguard Group Inc. purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,315,113 shares of the company's stock, valued at approximately $4,105,0August 19, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys $101,963.52 in StockAugust 15, 2024 | insidertrades.comBuy Recommendation for Cartesian Therapeutics on Robust Clinical Trials and Favorable Regulatory ProspectsAugust 14, 2024 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Price Target Cut to $45.00 by Analysts at HC WainwrightHC Wainwright dropped their target price on shares of Cartesian Therapeutics from $49.00 to $45.00 and set a "buy" rating for the company in a research note on Monday.August 12, 2024 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Releases Earnings Results, Beats Expectations By $1.35 EPSCartesian Therapeutics (NASDAQ:RNAC - Get Free Report) released its earnings results on Thursday. The company reported $0.54 EPS for the quarter, beating the consensus estimate of ($0.81) by $1.35. The business had revenue of $33.45 million for the quarter, compared to analysts' expectations of $6.00 million.August 11, 2024 | marketbeat.comBuy Rating Affirmed for Cartesian Therapeutics Amid Clinical Success and Strengthened FinancialsAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amid Promising Clinical Trials and Regulatory ProspectsAugust 9, 2024 | markets.businessinsider.comNeedham & Company LLC Lowers Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00Needham & Company LLC lowered their target price on Cartesian Therapeutics from $42.00 to $41.00 and set a "buy" rating on the stock in a report on Friday.August 9, 2024 | marketbeat.comBuy Rating Affirmed for Cartesian’s Innovative mRNA-based CAR-T Therapy Amidst Promising Clinical TrialsAugust 6, 2024 | markets.businessinsider.comTD Cowen Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationAugust 6, 2024 | msn.comCartesian Therapeutics (NASDAQ:RNAC) Now Covered by TD CowenTD Cowen assumed coverage on shares of Cartesian Therapeutics in a report on Tuesday. They set a "buy" rating on the stock.August 6, 2024 | marketbeat.comAmerican International Group Inc. Invests $37,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)American International Group Inc. purchased a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 56,202 shares of the compAugust 3, 2024 | marketbeat.comSG Americas Securities LLC Purchases Shares of 47,134 Cartesian Therapeutics, Inc. (NASDAQ:RNAC)SG Americas Securities LLC purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 47,134 shares of the company's stock, valued at appAugust 1, 2024 | marketbeat.comBNP Paribas Financial Markets Invests $38,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)BNP Paribas Financial Markets purchased a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 59,125 shares of the compaJuly 29, 2024 | marketbeat.com Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Click here to reserve your seat at the Crypto Community Summit. RNAC Media Mentions By Week RNAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼0.250.54▲Average Medical News Sentiment RNAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼153▲RNAC Articles Average Week Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMCR News Today OCUL News Today KNSA News Today DAWN News Today SPRY News Today XNCR News Today RCUS News Today NTLA News Today RCKT News Today TVTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredTrump Win = "Bull Trap"?Dan's research shows that the last time the market looked this way, not only did our economy suffer a large su...Stansberry Research | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
